Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Leases (2019 - 2025)

Northwest Biotherapeutics (NWBO) has 7 years of Operating Leases data on record, last reported at $4.4 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 7.89% year-over-year to $4.4 million; the TTM value through Sep 2025 reached $4.4 million, down 7.89%, while the annual FY2024 figure was $4.4 million, 0.36% changed from the prior year.
  • Operating Leases reached $4.4 million in Q3 2025 per NWBO's latest filing, down from $4.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.6 million in Q1 2021 and bottomed at $4.1 million in Q3 2022.
  • Average Operating Leases over 5 years is $4.7 million, with a median of $4.5 million recorded in 2023.
  • Peak YoY movement for Operating Leases: dropped 21.91% in 2022, then grew 16.79% in 2024.
  • A 5-year view of Operating Leases shows it stood at $5.2 million in 2021, then fell by 16.38% to $4.4 million in 2022, then increased by 1.92% to $4.5 million in 2023, then decreased by 0.36% to $4.4 million in 2024, then increased by 0.2% to $4.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $4.4 million in Q3 2025, $4.6 million in Q2 2025, and $4.5 million in Q1 2025.